A Markov model was designed to simulate outcomes of a hypothetical cohort of advanced (stage IIIB/IV) NSCLC adult patients with un-tested EGFR-sensitizing mutation status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.